La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Silk Road Medical Croissance future
Future contrôle des critères 1/6
Silk Road Medical is forecast to grow earnings and revenue by 3.6% and 9.4% per annum respectively. EPS is expected to grow by 4.6% per annum. Return on equity is forecast to be -39.5% in 3 years.
Informations clés
3.6%
Taux de croissance des bénéfices
4.6%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.4% |
| Taux de croissance des recettes | 9.4% |
| Rendement futur des capitaux propres | -39.5% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 13 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Silk Road Medical, Inc (NASDAQ:SILK) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 03
Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?
May 02Silk Road Medical, Inc's (NASDAQ:SILK) Shares Leap 35% Yet They're Still Not Telling The Full Story
Feb 03A Piece Of The Puzzle Missing From Silk Road Medical, Inc's (NASDAQ:SILK) 26% Share Price Climb
Dec 20Is Silk Road Medical (NASDAQ:SILK) Weighed On By Its Debt Load?
Nov 03Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?
Aug 05Shareholders Should Be Pleased With Silk Road Medical, Inc's (NASDAQ:SILK) Price
May 05Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?
Apr 04Silk Road Medical announces $100M common stock offering
Oct 17Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?
Sep 24Silk Road Medical GAAP EPS of -$0.44 beats by $0.02, revenue of $33.17M beats by $2.14M
Jul 26Silk Road Medical: Divergence From Alternative Risk Premia Means Lack Of Upside Capture
Jul 19Silk Road Medical falls after Citigroup downgrades to Sell from Neutral
Jul 11Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?
Jun 09Silk Road Medical - What A Road It Has Been
Apr 08Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 242 | -51 | -6 | -3 | 4 |
| 12/31/2025 | 221 | -54 | -10 | -8 | 7 |
| 12/31/2024 | 201 | -54 | -14 | -12 | 3 |
| 6/30/2024 | 191 | -57 | -36 | -34 | N/A |
| 3/31/2024 | 185 | -53 | -37 | -35 | N/A |
| 12/31/2023 | 177 | -56 | -34 | -32 | N/A |
| 9/30/2023 | 170 | -55 | -29 | -26 | N/A |
| 6/30/2023 | 163 | -53 | -27 | -24 | N/A |
| 3/31/2023 | 151 | -55 | -33 | -30 | N/A |
| 12/31/2022 | 139 | -55 | -38 | -33 | N/A |
| 9/30/2022 | 127 | -57 | -47 | -41 | N/A |
| 6/30/2022 | 114 | -61 | -50 | -43 | N/A |
| 3/31/2022 | 107 | -56 | -48 | -42 | N/A |
| 12/31/2021 | 101 | -50 | -44 | -39 | N/A |
| 9/30/2021 | 94 | -52 | -44 | -42 | N/A |
| 6/30/2021 | 90 | -48 | -41 | -40 | N/A |
| 3/31/2021 | 78 | -48 | -43 | -42 | N/A |
| 12/31/2020 | 75 | -47 | -43 | -42 | N/A |
| 9/30/2020 | 73 | -39 | -34 | -33 | N/A |
| 6/30/2020 | 70 | -37 | -36 | -35 | N/A |
| 3/31/2020 | 70 | -38 | -33 | -33 | N/A |
| 12/31/2019 | 63 | -52 | -30 | -30 | N/A |
| 9/30/2019 | 56 | -60 | -30 | -30 | N/A |
| 6/30/2019 | 49 | -61 | -31 | -30 | N/A |
| 3/31/2019 | 42 | -56 | -28 | -26 | N/A |
| 12/31/2018 | 35 | -38 | -24 | -22 | N/A |
| 12/31/2017 | 14 | -19 | N/A | -25 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: SILK is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: SILK is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: SILK is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: SILK's revenue (9.4% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: SILK's revenue (9.4% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: SILK is forecast to be unprofitable in 3 years.